

Decision Points for the 47th Board Meeting

Master List

Version 12 May 2022

#	Decision
1	Approval of the Rapporteur
2	Approval of the Agenda
3	Approval of the Revised Eligibility Policy
4	Approval of the Eligibility of the 2020-2022 Transition Funding Components for an Additional Allocation
5	Allocation Methodology 2023 - 2025
6	Catalytic Investments for the 2023-2025 Allocation Period
7	Board Leadership Term
8	Leveraging the work of the Standing Committees

Approval of the Rapporteur

Decision Point GF/B47/DP01: Approval of the Rapporteur

Mišo Pejković from the Eastern Europe and Central Asia Constituency is designated as Rapporteur for the 47th Board Meeting.

Signed:

Mišo Pejković
Rapporteur

Fady Zeidan
Secretariat

Approval of the Agenda

Decision Point GF/B47/DP02: Approval of the Agenda

The Agenda for the 47th Board Meeting (GF/B47/01) is approved.

Signed:

Mišo Pejković
Rapporteur

Fady Zeidan
Secretariat

Approval of the Revised Eligibility Policy

Decision Point GF/B47/DP03: Approval of the Revised Eligibility Policy

1. Based on the recommendation of the Strategy Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 1 to GF/B47/02 (the “Revised Eligibility Policy”).
2. Accordingly, the Board:
 - i. Acknowledges that this decision point and the Revised Eligibility Policy supersede the decision point GF/B39/DP03 and the previous Eligibility Policy as set forth in Annex 1 to GF/B39/02 (the “Previous Eligibility Policy”); and
 - ii. Notes that, notwithstanding paragraph 2.i of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2020-2022 allocation period.

Budgetary implications: None.

Signed:

Mišo Pejković
Rapporteur

Fady Zeidan
Secretariat

**Approval of the Eligibility of the 2020-2022 Transition Funding Components
for an Additional Allocation**

**Decision Point GF/B47/DP04: Approval of the Eligibility of the 2020-2022 Transition
Funding Components for an Additional Allocation**

Based on the recommendation of the Strategy Committee, the Board approves the eligibility of the six (6) Transition Funding components from the 2020-2022 allocation period for an additional allocation of Transition Funding for the 2023-2025 allocation period.

Budgetary implications: None

Signed:

Mišo Pejković
Rapporteur

Fady Zeidan
Secretariat

Decision Point GF/B47/DP05: Allocation Methodology 2023 - 2025

1. The Board notes:
 - a. Its decision in May 2019 (GF/B41/DP03) that (i) established the allocation methodology for the 2020 - 2022 allocation period; and (ii) acknowledged the technical parameters for the 2020 - 2022 allocation period; and
 - b. The decision by the Strategy Committee (the “SC”) in March 2022 GF/SC18/DP05, under authority delegated by the Board, to establish technical parameters for the 2023 – 2025 allocation period (the “Technical Parameters”).
2. Accordingly, based on the recommendations of the SC, as presented in GF/B47/03, the Board:
 - a. Approves the allocation methodology presented in Annex 1 to GF/B47/03 (the “Allocation Methodology”);
 - b. Acknowledges the Technical Parameters for the 2023 – 2025 allocation period, as presented in Annex 2 to GF/B47/03 and
 - c. Approves that no more than 7.5% of the total sources of funds available for country allocations be used to ensure scale-up, impact and paced reductions, as described in paragraph 4.c of the Allocation Methodology; and
3. Accordingly, the Board:
 - a. Requests the SC to review and approve, at its July 2022 meeting, the method by which the Secretariat will apply and report on the qualitative adjustment process; and
 - b. Acknowledges that the Allocation Methodology and Technical Parameters shall apply for the 2023– 2025 allocation period and supersede the 2020 – 2022 allocation methodology and technical parameters presented in GF/B41/02.

Budgetary implications (included in, or additional to, OPEX budget): None

Signed:

Mišo Pejković
Rapporteur

Fady Zeidan
Secretariat

Catalytic Investments for the 2023-2025 Allocation Period

Decision Point GF/B47/DP06: Catalytic Investments for the 2023-2025 Allocation Period

Based on the recommendation of the Strategy Committee, as presented in GF/B4704 – Revision 1, the Board:

1. Acknowledges that the total amount of sources of funds for allocation for the 2023-2025 allocation period will be decided by the Board in November 2022, based on the recommendation of the Audit and Finance Committee following announced replenishment results from the 7th Replenishment;
2. Approves that the total amount of funding for catalytic investments in the 2023-2025 allocation period (“Catalytic Investments”) will be determined by the total amount of sources of funds for allocation for the 2023-2025 allocation period;
3. Approves Catalytic Investments for the 2023 –2025 allocation period, based on the total amount of sources of funds for allocation, as set forth in Table 1 of GF/B47/DP06;
4. Agrees that in the event that sources of funds for allocation for the 2023-2025 allocation period are above the midpoint of the funding range specified for any scenario in Table 1 of GF/B47/DP06, the Secretariat may recommend to the Board to approve additional amounts for Catalytic Investments (up to 50% of the difference in total catalytic funding for the applicable scenario and the next higher funding scenario) to be invested in the priority areas for the next higher funding scenario in Table 1 of GF/B47/DP06;
5. Acknowledging that additional refinements may be required to the catalytic investment amounts for the priorities under the “RSSH/Cross-Cutting” section of Table 1 to GF/B47/DP06, delegates authority to the Strategy Committee to approve, within such RSSH/Cross-Cutting section (with the exclusion of the Emergency Fund priority): (i) a decrease in the amount of any priority by up to 15% and (ii) the inclusion of such decreased amounts within another priority in this group. Any changes made under this paragraph will be approved by the Strategy Committee at its July 2022 meeting, and will be informed by input to be provided by the Secretariat as described in paragraph 6.ii below
6. Approves that the Secretariat will:
 - i. operationalize Catalytic Investments, considering TRP and TERG recommendations as well as available program and financial performance data from ongoing catalytic investments, and work with partners to ensure that Catalytic Investments have clear objectives, expected outcomes and impact and transparency in the investment decisions on geographic prioritization and country selection;
 - ii. update the Strategy Committee, at its July 2022 meeting, on the status of such operationalization and planned next steps, and report, bi-annually, to the Strategy Committee and Board thereafter on further operationalization;

iii. have flexibility, within the total amount of funding for Catalytic Investments, to increase or decrease the amount for any approved priority up to 15% and report to the Strategy Committee on any such changes; and

iv. present any increase or decrease of an amount for any approved priority above 15% to the Strategy Committee for approval; and

7. Agrees that the Secretariat will have delegated authority to increase the amount of funding available for the Emergency Fund, by up to 50% of the amount approved for this priority, using funding approved as available by the Audit and Finance Committee for portfolio optimization, and that paragraph 6.iv above will not apply to increases to the Emergency Fund. Any increase above 50% will be presented to the Board for its urgent, no-objection approval.

Budgetary Implications: Associated management costs for Catalytic Investments will be covered by Catalytic Investments and/or operating expenses as applicable.

Table 1 to GF/B47/DP06:

Strategy Goal or Objective	Priority	Indicative Modality	US\$16 and Over	US\$15-16b	US\$14-15b	US\$13-14b	US\$12-13b
End AIDS	Prevention for key populations, AGYW and sexual partners	MF	\$107	\$87	\$78	\$73	\$24
	Implementation support for innovation, precision and scale in HIV prevention	SI	\$12	\$10	\$9	\$0	\$0
	Key populations sustainability and impact	MC	\$41	\$34	\$30	\$28	\$0
	HIV Incidence Reduction Total		\$160	\$131	\$117	\$101	\$24
End TB	Find and successfully treat the missing people with DS-TB and DR-TB	MF	\$179	\$161	\$152	\$123	\$82
	Scale up TB prevention	MF	\$54	\$48	\$45	\$37	\$0
	Country readiness for innovation and quality TB programming	MF	\$18	\$16	\$15	\$12	\$0
	Technical support to the TB matching funds	SI	\$16	\$13	\$12	\$11	\$0
	End TB: Accelerate progress to End TB by 2030 Total		\$267	\$238	\$224	\$183	\$82
End Malaria	Biologic threats in malaria case management in Africa	SI	\$20	\$16	\$14	\$13	\$0
	E2030: Drive towards elimination and facilitate prevention of reestablishment	SI	\$7	\$6	\$5	\$0	\$0
	Malaria Elimination in Southern Africa	MC, MF	\$13	\$11	\$10	\$10	\$0
	Resistance to Artemisinin Initiative (RAI)	MC	\$110	\$100	\$100	\$80	\$50
	Regional Coordination and targeted Technical Assistance (RCTA)	SI	\$9	\$7	\$7	\$0	\$0
	Addressing vector control threats and opportunities: supporting country readiness for an expanding toolbox	SI	\$16	\$13	\$12	\$11	\$0
	Malaria Total		\$175	\$153	\$148	\$114	\$50
Maximizing People-centered Integrated Systems for Health	Empowering regional reference laboratories and national diagnostic networks	SI, MC	\$33	\$27	\$24	\$0	\$0
	Data	SI	\$29	\$24	\$21	\$0	\$0
	Equitable access to quality health products through innovation, partnership, and promoting sustainable sourcing and supply chains at global, national and community levels (NextGen Market Shaping)	SI, MF	\$140	\$85	\$49	\$23	\$0
	Incentivizing RSSH quality and scale	MF	\$60	\$40	\$30	\$20	\$0
Maximizing Health Equity, Gender Equality and Human	Effective community systems & responses (CS&R) contributing to improved health outcomes, equitable access to integrated people-centered quality services	MF, SI	\$90	\$74	\$66	\$61	\$0
	Community engagement	SI	\$20	\$18	\$18	\$15	\$14
Mobilizing Increased Resources	Scaling up programs to remove human rights and gender related barriers	MF, SI	\$49	\$40	\$36	\$33	\$20
	Health Financing	SI	\$37	\$30	\$27	\$20	\$0
End AIDS, TB, Malaria	Emergency Fund	SI	\$40	\$40	\$40	\$30	\$10
	RSSH / Cross-Cutting Total		\$498	\$378	\$311	\$202	\$44
Amounts in US\$m	TOTAL		\$1,100	\$900	\$800	\$600	\$200

Signed:

Mišo Pejković
Rapporteur

Fady Zeidan
Secretariat

Board Leadership Term

Decision Point GF/B47/DP07: Board Leadership Term

The Board approves the amendments to the (i) Terms of Reference Chair and Vice-Chair of the Board of the Global Fund, (ii) Bylaws of the Global Fund; and (iii) the Operating Procedures of the Board and Committees of the Global Fund, set out respectively in annexes 1, 2 and 3 to GF/B47/05.

Budgetary implications (included in OPEX budget)

Signed:

Mišo Pejković
Rapporteur

Fady Zeidan
Secretariat

Leveraging the work of the Standing Committees

Decision Point GF/B47/DP08: Leveraging the work of the Standing Committees

Based on the recommendation of the Ethics and Governance Committee (the “EGC”), as presented in GF/B47/06 – Revision 1, the Board:

1. Acknowledges the changes to the Charter of the Strategy Committee already approved through GF/B46/DP06 and which will be effective as of 31 December 2022;
2. Amends the Charters of the Standing Committees of the Board (“the Charters”), as set forth respectively in Annexes 5, 6 and 7 of GF/B47/06 – Revision 1, which shall each become effective upon the conclusion of the forty-seventh Board meeting; and
3. Acknowledging the specific scope and intent of the changes to the Charters, requests the EGC leadership to determine, after consultation with the Board leadership, Coordinating Group, Standing Committees and Secretariat, as relevant, whether a more complete review of the Charters may be required during the next EGC term.

There are not any budgetary implications additional to OPEX budget

Signed:

Mišo Pejković
Rapporteur

Fady Zeidan
Secretariat